Tomas de Wouters
Overview
Explore the profile of Tomas de Wouters including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
1047
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anthamatten L, von Bieberstein P, Menzi C, Zund J, Lacroix C, de Wouters T, et al.
Microbiome
. 2024 Oct;
12(1):186.
PMID: 39350289
Background: The human gut microbiome produces and consumes a variety of compounds that interact with the host and impact health. Succinate is of particular interest as it intersects with both...
2.
Zund J, Pluss S, Mujezinovic D, Menzi C, von Bieberstein P, de Wouters T, et al.
ISME Commun
. 2024 Apr;
4(1):ycae035.
PMID: 38562261
The anaerobic cultivation of fecal microbiota is a promising approach to investigating how gut microbial communities respond to specific intestinal conditions and perturbations. Here, we describe a flexible protocol using...
3.
Asare P, Lee C, Hurlimann V, Teo Y, Cuenod A, Akduman N, et al.
Front Microbiol
. 2023 Jun;
14:1208177.
PMID: 37283928
[This corrects the article DOI: 10.3389/fmicb.2023.1104707.].
4.
Asare P, Lee C, Hurlimann V, Teo Y, Cuenod A, Akduman N, et al.
Front Microbiol
. 2023 Mar;
14:1104707.
PMID: 36896425
Introduction: Microbial isolates from culture can be identified using 16S or whole-genome sequencing which generates substantial costs and requires time and expertise. Protein fingerprinting Matrix-assisted Laser Desorption Ionization-time of flight...
5.
Kurt F, Leventhal G, Spalinger M, Anthamatten L, von Bieberstein P, Menzi C, et al.
Gut Microbes
. 2023 Feb;
15(1):2177486.
PMID: 36794804
The success of fecal microbiota transplants (FMT) has provided the necessary proof-of-concept for microbiome therapeutics. Yet, feces-based therapies have many associated risks and uncertainties, and hence defined microbial consortia that...
6.
Hitch T, Hall L, Walsh S, Leventhal G, Slack E, de Wouters T, et al.
Mucosal Immunol
. 2022 Sep;
15(6):1095-1113.
PMID: 36180583
The gut microbiome lies at the intersection between the environment and the host, with the ability to modify host responses to disease-relevant exposures and stimuli. This is evident in how...
7.
Montalban-Arques A, Katkeviciute E, Busenhart P, Bircher A, Wirbel J, Zeller G, et al.
Cell Host Microbe
. 2021 Aug;
29(10):1573-1588.e7.
PMID: 34453895
Despite overall success, T cell checkpoint inhibitors for cancer treatment are still only efficient in a minority of patients. Recently, intestinal microbiota was found to critically modulate anti-cancer immunity and...
8.
Bosley K, Casebourn C, Chan P, Chen J, Chen M, Church G, et al.
Nat Biotechnol
. 2021 Jul;
39(8):1017.
PMID: 34290438
No abstract available.
9.
Bosley K, Casebourn C, Chan P, Chen J, Chen M, Church G, et al.
Nat Biotechnol
. 2021 Jun;
39(6):654-660.
PMID: 34113035
No abstract available.
10.
Otaru N, Ye K, Mujezinovic D, Berchtold L, Constancias F, Cornejo F, et al.
Front Microbiol
. 2021 May;
12:656895.
PMID: 33936013
The high neuroactive potential of metabolites produced by gut microbes has gained traction over the last few years, with metagenomic-based studies suggesting an important role of microbiota-derived γ-aminobutyric acid (GABA)...